Henry Schein (NASDAQ:HSIC) Releases FY 2024 Earnings Guidance

Henry Schein (NASDAQ:HSIC) issued an update on its FY 2024 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 4.740-4.740 for the period, compared to the consensus estimate of 4.770. The company issued revenue guidance of $12.7 billion-$12.7 billion, compared to the consensus revenue estimate of $12.8 billion. Henry Schein also updated its Q4 2024 guidance to 1.190-1.190 EPS.

Henry Schein Trading Up 0.2 %

NASDAQ:HSIC opened at $80.03 on Friday. Henry Schein has a 12-month low of $63.67 and a 12-month high of $82.63. The firm has a market cap of $9.98 billion, a PE ratio of 32.93, a price-to-earnings-growth ratio of 2.20 and a beta of 0.89. The company has a current ratio of 1.42, a quick ratio of 0.82 and a debt-to-equity ratio of 0.46. The stock has a fifty day moving average price of $73.31 and a 200 day moving average price of $71.34.

Henry Schein (NASDAQ:HSIC) last issued its earnings results on Tuesday, November 5th. The company reported $1.22 EPS for the quarter, topping analysts’ consensus estimates of $1.17 by $0.05. The firm had revenue of $3.17 billion during the quarter, compared to the consensus estimate of $3.24 billion. Henry Schein had a net margin of 2.51% and a return on equity of 12.90%. The company’s revenue was up .4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.32 earnings per share. Sell-side analysts anticipate that Henry Schein will post 4.74 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on HSIC shares. Jefferies Financial Group boosted their price objective on shares of Henry Schein from $77.00 to $80.00 and gave the stock a “hold” rating in a research report on Thursday, January 23rd. Evercore ISI raised their price objective on Henry Schein from $70.00 to $74.00 and gave the stock an “in-line” rating in a report on Tuesday, October 8th. Bank of America raised Henry Schein from an “underperform” rating to a “buy” rating and boosted their target price for the company from $69.00 to $84.00 in a report on Monday, January 6th. StockNews.com upgraded Henry Schein from a “sell” rating to a “hold” rating in a research note on Thursday, November 7th. Finally, Barrington Research boosted their price objective on Henry Schein from $82.00 to $90.00 and gave the company an “outperform” rating in a research note on Thursday. Seven research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Henry Schein has a consensus rating of “Moderate Buy” and a consensus price target of $80.10.

Insider Buying and Selling at Henry Schein

In other Henry Schein news, COO Michael S. Ettinger sold 12,240 shares of the firm’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $75.00, for a total value of $918,000.00. Following the completion of the sale, the chief operating officer now owns 87,706 shares of the company’s stock, valued at approximately $6,577,950. This trade represents a 12.25 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.14% of the stock is owned by corporate insiders.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.